Avidity's Spinoff and Novartis Deal

Novartis AG acquires Avidity Biosciences for $72/share ($12B valuation).
Deal boosts Novartis' xRNA/ neuroscience strategy and sales CAGR to 6%.
Avidity spins off cardiology assets into SpinCo with $270M and leaders Gallagher/Boyce.
Merger expected to close in Q1 2026, pending approvals.
Press release warns of regulatory, SpinCo, and R&D risks.

Spinoff | Strategy | Acquisition

United States | Switzerland

Kathleen Gallagher | Sarah Boyce

1 week ago